The rise of immuno-oncology in China: a challenge to western dominance?

Lythgoe, Mark P; Lewison, Grant; Aggarwal, Ajay; Booth, Chris; Lawler, Mark; Trapani, Dario; Sengar, Manju; Sullivan, Richard

Lythgoe, Mark P; Lewison, Grant; Aggarwal, Ajay; Booth, Chris; Lawler, Mark; Trapani, Dario; Sengar, Manju; Sullivan, Richard.

Afiliação

Lythgoe MP; Department of Surgery and Cancer, Imperial College London, London, UK. Electronic address: M.Lythgoe@imperial.ac.uk.
Lewison G; King's College London, Institute of Cancer Policy (Global Oncology Group), London, UK.
Aggarwal A; Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK.
Booth C; Departments of Oncology & Public Health Sciences, Queen's University, Kingston, ON, Canada.
Lawler M; Patrick G Johnston Centre for Cancer Research, Faculty of Medicine, Health and Life Sciences, Queen's University Belfast, Belfast, UK.
Trapani D; Division of Early Drug Development for Innovative Therapies, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
Sengar M; Department of Medical Oncology, Tata Memorial Centre, Mumbai, India.
Sullivan R; King's College London, Institute of Cancer Policy (Global Oncology Group), London, UK.

Lancet Oncol ; 24(5): 439-441, 2023 05.

Article em En | MEDLINE | ID: mdl-37142369

Assuntos

Neoplasias; Humanos; Neoplasias/epidemiologia; Neoplasias/terapia; Oncologia; China/epidemiologia; Imunoterapia/efeitos adversos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Limite: Humans País/Região como assunto: Asia Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google